BioMarin Breaks Out $287.7 Million In Drug-Buying Costs, With A $70.0 Million Charge Still To Come
The rare-disease drugmaker now books acquired pipeline spending apart from R&D, and the October Fabry license adds to the fourth quarter.
BioMarin, the rare-disease drugmaker, now reports what it pays to buy drug candidates as its own expense line, which came to $287.7 million in the third quarter against $221.0 million a year earlier, according to its quarterly report filed Tuesday. A further $70.0 million charge is due in the fourth quarter from an October license for a Fabry disease drug.
A new line on the income statement
Acquired in-process research and development, the cost of buying rights to unfinished drug projects, used to sit inside research and development. BioMarin says the separate line gives a clearer view of upfront and milestone payments made to acquire projects.
The company moved last year's $221.0 million out of R&D to match. Total operating expenses, net income and per-share results did not change, the 10-Q says. The second-quarter filing had counted that spending within R&D.
The third-quarter figure includes about $282.3 million for BMN 440, an oral drug candidate for hypophosphatasia, a rare genetic bone disease. BioMarin got it by completing its purchase of Alesta Therapeutics on August 31 for $303.4 million, treated as an asset acquisition, with up to $215 million more in regulatory and sales milestones. The prior-year charge was tied to BMN 401, which the company later chose to stop developing.
A Fabry license adds $70.0 million
In October, BioMarin licensed BMN 450, an investigational long-acting enzyme therapy for Fabry disease, from GC Biopharma and Hanmi. It will pay $70.0 million upfront, which it expects to book as acquired IPR&D in the fourth quarter, and the partners can earn up to $405.0 million more in milestones plus tiered royalties.
Separately, the company says other license milestones it considers reasonably possible total $485.5 million, of which up to $7.5 million could be paid over the next twelve months.
Paying for a buying spree with debt
BioMarin develops and sells medicines for rare genetic diseases, including VOXZOGO for achondroplasia and enzyme therapies such as VIMIZIM and NAGLAZYME. It financed its roughly $5.3 billion Amicus purchase in April with new term loans and notes, lifting debt to about $4.2 billion as of September 30.
The quarter shows the cost. BioMarin posted a net loss of $122.8 million on revenue of $1.02 billion, with interest expense of $55.6 million, up from $2.6 million a year ago, and intangible amortization of $99.5 million, up from $4.8 million. Total revenues rose from $776.1 million.
The $600.0 million of 1.25% convertible notes due in May 2027 must be repaid in cash unless converted, repurchased or refinanced.
Fourth-quarter results will carry the $70.0 million BMN 450 charge, which BioMarin says will push acquired IPR&D higher.
Sources
- 10-Q Filing — BioMarin Pharmaceutical (BMRN) — SEC EDGAR
- 10-Q Filing — BioMarin Pharmaceutical (BMRN), Q2 FY2026 filed 2026-08-06 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, earningsrelease-2nov26ex991.htm) — BioMarin Pharmaceutical, filed 2026-11-02 — SEC EDGAR
More on BioMarin Pharmaceutical
- BioMarin Sets 2026 Revenue Range At $3.8 Billion To $3.9 Billion As One Customer Defers $70 Million
- BioMarin Passes $1 Billion In Quarterly Revenue, Then Cuts Its 2026 Profit Outlook To $2.80-$3.10 A Share
- BioMarin's Alesta Purchase Will Cost $320 Million In 2026, Its 8-K Says, And The Forecast Excludes It